

Contents

CHAPTER 1

The Pathology of Asthma: An Overview

L.A. LAITINEN and A. LAITINEN. With 10 Figures 1

A. Introduction 1

B. Methods to Investigate the Pathology of Human Asthma 1

C. Bronchial Epithelium and Inflammatory Cells
in Asthmatic Patients Between Attacks 2

 I. Mast Cells 4

 II. Eosinophils 7

 III. Neutrophils 10

D. Bronchial Epithelial Inflammation During an Asthma Attack 10

E. Epithelial Regeneration 12

F. Airway Smooth Muscle 13

G. Bronchial Glands 13

H. Neural Pathways 14

 I. Epithelium 14

 II. Neuroepithelial Bodies and Neuroendocrine-Like
 (Granule-Containing) Cells 15

I. Nerves and Other Airway Structures 16

J. Bronchial Circulation 16

K. Leakage of the Bronchial Vascular Bed in Patients
 with Asthma 17

L. Conclusion 19

References 20

CHAPTER 2

The Contribution of Inflammatory Cells to the Pathogenesis of Asthma

A.G. ALEXANDER, J.W. WILSON, S.T. HOLGATE, and A.B. KAY.
With 5 Figures 27

A. Inflammation and Inflammatory Cells 27

B. Pathological Evidence for Inflammation in Asthma 28

C. Microvascular Leakage 29

D. Neutrophils 30

- E. Eosinophils 32
- F. Mast Cells and Basophils 35
- G. Monocytes and Macrophages (Mononuclear Phagocytes) 37
- H. Platelets 38
- I. Lymphocytes 39
- J. *Concluding Comments* 42
- References 44

CHAPTER 3

Inflammatory Mediators

- P.J. BARNES, K.F. CHUNG, and C.P. PAGE. With 5 Figures 53

- A. Introduction 53
 - I. Cellular Origin of Mediators 53
 - II. Mediator Effects 54
 - III. Mediator Receptors 55
 - IV. Mediator Interactions 57
 - V. Mediator Antagonists 57
- B. Histamine 57
 - I. Synthesis and Metabolism 58
 - II. Histamine Receptors 58
 - III. Airway Effects 59
 - IV. Role in Asthma 60
- C. Cyclooxygenase Products 61
 - I. Synthesis and Metabolism 61
 - II. Receptors 63
 - III. Airway Effects 63
 - 1. Airway Smooth Muscle 63
 - 2. Secretion 64
 - 3. Inflammatory Effects 64
 - IV. Role in Asthma 64
- D. Lipoyxygenase Products 65
 - I. Synthesis and Metabolism 65
 - II. Receptors 66
 - III. Airway Effects 67
 - 1. Airway Smooth Muscle 67
 - 2. Secretion 67
 - 3. Vascular Effects 67
 - 4. Cellular Activation 68
 - 5. Effects on Bronchial Responsiveness 68
 - IV. Role in Asthma 68
- E. PAF 69
 - I. Origin 69
 - 1. Synthesis 69
 - 2. Cellular Origin 70
 - 3. Metabolism 70

II. Receptors	71
III. Airway Effects	71
1. Airway Smooth Muscle	71
2. Airway Secretions	72
3. Vascular Effects	72
4. Inflammatory Cell Activation	73
5. Bronchial Hyperresponsiveness	74
IV. Role in Asthma	75
1. Release of PAF in Asthma	75
2. PAF Antagonists	77
F. Kinins	78
I. Formation and Metabolism	78
II. Receptors	79
III. Airway Effects	79
IV. Role in Asthma	80
G. Adenosine	81
I. Origin	81
II. Receptors	81
III. Actions	81
IV. Role in Asthma	82
H. Complement	82
I. Origin and Metabolism	82
II. Receptors	83
III. Airway Effects	83
1. Smooth Muscle Contraction	83
2. Vascular Effects	84
3. Mucus Secretion	84
4. Chemotaxis and Cell Activation	84
5. Bronchial Hyperresponsiveness	84
IV. Role in Asthma	85
I. Serotonin	85
I. Origin	85
II. Receptors	86
III. Airway Effects	86
J. Chemotactic Factors	86
K. Oxygen Radicals	87
L. Conclusions	88
References	89

CHAPTER 4

Pharmacology of Airway Smooth Muscle

I.W. RODGER and R.C. SMALL. With 6 Figures	107
A. Introduction	107
B. E/C Coupling Mechanisms	107

I. The Airway Smooth Muscle Cell	107
II. Activator Calcium Ions and E/C Coupling	108
1. Coupling Mechanisms	108
2. Extracellular Activator Ca^{2+}	109
3. Intracellular Activator Ca^{2+}	111
III. Biochemical Basis of Airway Smooth Muscle Contraction	114
C. E/C Uncoupling Mechanisms	119
I. β -Adrenoceptor Agonists	120
1. β -Agonist-Induced Relaxation In Vitro: General Properties ..	120
2. Role of Cyclic Adenosine Monophosphate (cAMP) Accumulation in the Relaxant Actions of β -Adrenoceptor Agonists	120
3. β -Agonists and the Ca^{2+} Sensitivity (or Responsiveness) of the Contractile Machinery	121
4. β -Agonists and Inhibition of Ca^{2+} Influx	122
5. β -Agonists and Inhibition of Ca^{2+} Release from Intracellular Stores	125
6. β -Agonists and Promotion of Ca^{2+} Sequestration by Intracellular Stores	126
7. β -Agonists and Ca^{2+} Extrusion	127
II. Alkylxanthines	127
1. Alkylxanthine-Induced Relaxation In Vitro: General Properties	127
2. Role of cAMP Accumulation in the Relaxant Actions of Alkylxanthines	127
3. Alkylxanthines and Reduction in the Ca^{2+} Sensitivity (or Responsiveness) of the Contractile Machinery	129
4. Alkylxanthines and Inhibition of Ca^{2+} Influx	129
5. Alkylxanthines and Inhibition of Ca^{2+} Release from Intracellular Stores	130
6. Alkylxanthines and Promotion of Ca^{2+} Sequestration by Intracellular Stores	132
7. Alkylxanthines and Ca^{2+} Extrusion	133
D. Future Trends in the Development of Bronchodilator Drugs	133
References	134

CHAPTER 5

Neural Mechanisms in Asthma

P.J. BARNES. With 9 Figures	143
A. Introduction	143
B. Cholinergic Mechanisms	145
I. Increased Vagal Tone	145
II. Reflex Bronchoconstriction	145

III. Increased Acetylcholine Release	147
IV. Muscarinic Receptors	147
V. Cholinergic Mechanisms in Asthma	148
VI. Cholinergic Mechanisms in COAD	148
VII. Muscarinic Receptor Subtypes	148
C. Adrenergic Mechanisms	151
I. Adrenergic Innervation	151
II. Circulating Catecholamines	151
III. β -Adrenoceptors	152
IV. α -Adrenoceptors	153
D. NANC Nerves and Neuropeptides	154
I. NANC Inhibitory Nerves	154
II. Increased NANC Excitatory Nerves	155
III. Tachykinins	155
IV. Calcitonin Gene-Related Peptide	157
V. Axon Reflex Mechanisms	158
VI. Modulation of NANC Bronchoconstriction	159
E. Conclusions	159
References	159

CHAPTER 6

Pharmacology and Therapeutics of β -Adrenoceptor Agonists

R.G. GOLDIE, J.W. PATERSON, and K.M. LULICH. With 2 Figures	167
A. Introduction	167
B. The Molecular Nature of the β -Adrenoceptor and Its Relationship to Adenylate Cyclase	167
I. The β -Adrenoceptor	168
II. Regulatory Proteins	169
III. Adenylate Cyclase	169
IV. β -Adrenoceptor Desensitization	169
C. Density and Distribution of β -Adrenoceptors in the Lung	170
I. Radioligand Binding Studies	170
II. Autoradiography	171
1. Trachea	171
2. Parenchyma	171
D. Therapeutic Sites of Action	172
I. Airway Smooth Muscle	172
II. Secretory Cells and Cilia	173
III. Tracheobronchial Microvessels	174
IV. Cholinergic Nerves	175
V. Mast Cells	175
VI. Inflammatory Cells	176

1. Eosinophils	176
2. Lymphocytes	177
3. Polymorphonuclear Leukocytes	178
4. Macrophages	178
5. Platelets	178
6. Anti-Inflammatory Action in Asthmatic Airways	179
E. The Status of β -Adrenoceptor Function in Asthma	179
I. In Vivo Studies	180
II. In Vitro Studies	180
1. Isolated Human Leukocytes	180
2. Isolated Human Bronchi	181
3. Radioligand Binding Studies and Autoradiography in Lung	182
F. The Importance of β_2 -Adrenoceptor Selectivity and Efficacy	183
I. β_2 Selectivity	183
II. Efficacy	184
G. Adverse Reactions to β -Adrenoceptor Agonists	185
I. Skeletal Muscle Tremor	185
II. Cardiac Effects	185
III. Changes in Plasma Constituents	186
1. Potassium	186
2. Glucose	186
3. Lipids	186
IV. PaO_2	186
V. Neuropharmacological Effects	187
VI. Hypersensitivity	187
H. Therapeutic Actions of β -Agonists	187
I. Adrenaline	187
II. Ephedrine	189
III. Isoprenaline	189
IV. Selective β_2 -Agonists	190
V. Prodrugs	191
VI. Clinical Application	191
I. Concluding Remarks	194
References	195

CHAPTER 7

Pharmacology of Anti-Asthma Xanthines

C.G.A. PERSSON and R. PAUWELS. With 2 Figures	207
A. Introduction	207
I. Developmental Aspects	207
II. Chemistry and Subdivision of Xanthines	209
B. Clinical Use	211

I. Acute Severe Asthma	211
II. Chronic Asthma	211
III. Chronic Obstructive Pulmonary Disorders	213
C. Mode of Action of Xanthines	215
I. Smooth Muscle Relaxation or Inhibition?	215
II. Airway Anti-Inflammatory Actions	216
III. Anti-Asthma Actions Outside the Airways?	217
IV. Subcellular Mechanisms of Action	218
V. Role of Endogenous Adenosine	219
D. Conclusion	220
References	221

CHAPTER 8

Glucocorticosteroids in Asthma

S.F. SMITH, C.P. PAGE, P.J. BARNES, and R.J. FLOWER	227
---	-----

A. Mechanism of Action of Glucocorticosteroids	227
I. Induction of Protein Synthesis	227
1. Lipocortins	228
2. Other Proteins Modulated by Glucocorticosteroids	237
II. Effects on Cell Activation and Recruitment	239
III. Other Effects	242
1. Vascular Permeability and Effects on Vascular Endothelium	242
2. Effects on β -Adrenoceptors	242
3. Effects on Airway Function	243
B. Clinical Use	247
I. Pharmacokinetics of Steroids	247
II. Routes of Administration	248
1. Oral	248
2. Intravenous	248
3. Inhaled	248
III. Side Effects	249
1. Adrenal Suppression	249
2. Systemic Side Effects	249
3. Local Side Effects	250
IV. Use in Clinical Practice	250
1. Acute Asthma	250
2. Chronic Asthma	250
C. Future Developments	251
References	251

CHAPTER 9

Pharmacology of Prophylactic Anti-Asthma Drugs

L.G. GARLAND	261
A. Cromoglycate and Nedocromil	261
I. Cellular Pharmacology	262
1. Mast Cells and Basophils	262
2. Neutrophils, Eosinophils, Monocytes, and Platelets	264
II. Biochemical Pharmacology	266
III. Animal Pharmacology	267
1. Anaphylactic Bronchospasm	267
2. Sensory Reflexes	268
IV. Human Pharmacology	269
B. Ketotifen	272
I. Pharmacology In Vitro	272
II. Animal Pharmacology	274
1. Antihistamine, Antiallergic Properties	274
2. Inhibition of PAF-Induced Airway Hyperreactivity	274
III. Human Pharmacology	275
1. Blockade of Responses to Spasmogens and Allergens	275
2. Reversal of β -Adrenergic Receptor Tachyphylaxis	275
3. Double-Blind Placebo-Controlled Clinical Trials	276
C. Pharmacological Analysis	278
I. Cromoglycate and Nedocromil	278
II. Ketotifen	280
References	280

CHAPTER 10

Pathophysiology and Pharmacology of Aspirin-Induced Asthma

A. SZCZEKLIK, C. VIRCHOW, and M. SCHMITZ-SCHUMANN. With 6 Figures	291
A. Introduction	291
B. Definition and Main Clinical Features	291
I. Major Offenders and Safe Alternatives	292
II. Salicylates	292
III. Paracetamol	294
IV. Pyrazolones	294
V. Tartrazine	295
VI. Glucocorticosteroids	295
C. Pathogenesis	297
I. Allergic Mechanisms	297
II. Abnormal Reactivity of Bradykinin Receptors	297
III. Acetylation of Proteins	298
IV. Complement Involvement	298
V. The Cyclooxygenase Theory	298

1. Formulation of the Theory	298
2. Early Explanations	300
3. Participation of LTs	301
4. Platelet Involvement	303
5. Compartmentalization of Eicosanoids in the Lungs	304
6. Viral Infection	304
D. Diagnosis	306
E. Prevention and Therapy	307
References	309
 Subject Index	 315